CME Group (CME)
NASDAQFinancialsFinancial - Data & Stock ExchangesSnapshot 2026-10-29
$303.14+2.27%
Close 2026-10-30 · 1-day change
NASDAQFinancialsFinancial - Data & Stock ExchangesSnapshot 2026-10-29
Research Workspace
Put CME beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Financials is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Achieve record revenue growth near $6.5B in FY26: Revenue: $1.74B.
View ThesisRevenue is growing steadily — about 9% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look high — the market is pricing in about 17% growth a year, above the roughly 6% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskCME’s case rests on expanding trading volumes and record revenue, though the primary revenue pillar is under pressure. Recent earnings beats support execution, but reported revenue growth is not provided here. CME trades at 24× P/E versus a 12× peer median and its 22× history. The market is pricing in more growth than our forecast. The model puts the next-quarter miss probability near 19%. The multiple premium must be earned, especially with the primary FY26 record-revenue pillar under pressure. Peer multiples imply a price about 17% below where it trades; the thesis is on watch.
Trailing returns as of 2026-10-30. CME is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 18 analysts currently covering CME (as of Oct 2026).
Based on 7 Wall Street analysts offering 12-month price targets for CME in the last 4 months.
Continue this research
Compare CME with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CME Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Financial Exchanges & Data — fair value, gap to price, and forward P/E.
Compare the value case
Put CME next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Expand product offerings and market access
Securities-clearing launch expands offerings; reported 29.4M Q3 ADV supports trading-volume growth.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $303.14
The last 12 months of price, then the range of analyst 12-month targets from today’s $303.14.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Earnings beat is offset by guidance concerns, creating a credible headwind to growth expectations.
CFTC resistance raises regulatory uncertainty for CME's perpetual-futures efforts and potential product expansion.
Advances: Expand product offerings and market access
New futures expand CME’s product range, but the launch alone does not establish meaningful adoption.
Advances: Increase average daily trading volume (ADV)
New volume record supports growth in average daily trading volume.
Advances: Expand product offerings and market access
Cloud testing supports product expansion and market access.
Advances: Achieve record revenue and earnings
Analyst upgrade reflects positive growth outlook for CME.
Advances: Expand product offerings and market access
New product launch aligns with expansion objectives.
